Hepatitis B - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 385 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatitis B - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Hepatitis B - Pipeline Review, H2 2015', provides an overview of the Hepatitis B's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatitis B
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hepatitis B and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hepatitis B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatitis B pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatitis B
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 7
Hepatitis B Overview 8
Therapeutics Development 9
Hepatitis B - Therapeutics under Development by Companies 11
Hepatitis B - Therapeutics under Investigation by Universities/Institutes 19
Hepatitis B - Pipeline Products Glance 20
Hepatitis B - Products under Development by Companies 24
Hepatitis B - Products under Investigation by Universities/Institutes 33
Hepatitis B - Companies Involved in Therapeutics Development 34
Hepatitis B - Therapeutics Assessment 116
Drug Profiles 127
Hepatitis B - Recent Pipeline Updates 308
Hepatitis B - Dormant Projects 349
Hepatitis B - Discontinued Products 358
Hepatitis B - Product Development Milestones 359
Appendix 367

List of Tables

Number of Products under Development for Hepatitis B, H2 2015 26
Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2015 27
Number of Products under Development by Companies, H2 2015 29
Number of Products under Development by Companies, H2 2015 (Contd..1) 30
Number of Products under Development by Companies, H2 2015 (Contd..2) 31
Number of Products under Development by Companies, H2 2015 (Contd..3) 32
Number of Products under Development by Companies, H2 2015 (Contd..4) 33
Number of Products under Development by Companies, H2 2015 (Contd..5) 34
Number of Products under Development by Companies, H2 2015 (Contd..6) 35
Number of Products under Investigation by Universities/Institutes, H2 2015 36
Comparative Analysis by Late Stage Development, H2 2015 37
Comparative Analysis by Clinical Stage Development, H2 2015 38
Comparative Analysis by Early Stage Development, H2 2015 39
Comparative Analysis by Unknown Stage Development, H2 2015 40
Products under Development by Companies, H2 2015 41
Products under Development by Companies, H2 2015 (Contd..1) 42
Products under Development by Companies, H2 2015 (Contd..2) 43
Products under Development by Companies, H2 2015 (Contd..3) 44
Products under Development by Companies, H2 2015 (Contd..4) 45
Products under Development by Companies, H2 2015 (Contd..5) 46
Products under Development by Companies, H2 2015 (Contd..6) 47
Products under Development by Companies, H2 2015 (Contd..7) 48
Products under Development by Companies, H2 2015 (Contd..8) 49
Products under Investigation by Universities/Institutes, H2 2015 50
Hepatitis B - Pipeline by Abivax S.A., H2 2015 51
Hepatitis B - Pipeline by AiCuris GmbH & Co. KG, H2 2015 52
Hepatitis B - Pipeline by AIMM Therapeutics B.V., H2 2015 53
Hepatitis B - Pipeline by Akshaya Bio Inc., H2 2015 54
Hepatitis B - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 55
Hepatitis B - Pipeline by AlphaMab Co., Ltd, H2 2015 56
Hepatitis B - Pipeline by Altimmune, Inc., H2 2015 57
Hepatitis B - Pipeline by AltraVax Inc., H2 2015 58
Hepatitis B - Pipeline by Amarna Therapeutics B.V., H2 2015 59
Hepatitis B - Pipeline by Arbutus Biopharma Corporation, H2 2015 60
Hepatitis B - Pipeline by Arrowhead Research Corporation, H2 2015 61
Hepatitis B - Pipeline by Assembly Biosciences, Inc., H2 2015 62
Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 63
Hepatitis B - Pipeline by Benitec Biopharma Limited, H2 2015 64
Hepatitis B - Pipeline by BioDiem Ltd, H2 2015 65
Hepatitis B - Pipeline by Biogenomics Limited, H2 2015 66
Hepatitis B - Pipeline by Biological E. Limited, H2 2015 67
Hepatitis B - Pipeline by BioStar Pharmaceuticals, Inc., H2 2015 68
Hepatitis B - Pipeline by Bolder Biotechnology, Inc., H2 2015 69
Hepatitis B - Pipeline by Bukwang Pharm.Co., Ltd., H2 2015 70
Hepatitis B - Pipeline by CaroGen Corporation, H2 2015 71
Hepatitis B - Pipeline by CEL-SCI Corporation, H2 2015 72
Hepatitis B - Pipeline by Celltrion, Inc., H2 2015 73
Hepatitis B - Pipeline by Chimerix, Inc., H2 2015 74
Hepatitis B - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015 75
Hepatitis B - Pipeline by ChronTech Pharma AB, H2 2015 76
Hepatitis B - Pipeline by Cocrystal Pharma, Inc., H2 2015 77
Hepatitis B - Pipeline by Cytos Biotechnology AG, H2 2015 78
Hepatitis B - Pipeline by CyTuVax B.V., H2 2015 79
Hepatitis B - Pipeline by Dong-A ST Co., Ltd., H2 2015 80
Hepatitis B - Pipeline by Dynavax Technologies Corporation, H2 2015 81
Hepatitis B - Pipeline by Ensemble Therapeutics Corporation, H2 2015 82
Hepatitis B - Pipeline by Enyo Pharma S.A.S., H2 2015 83
Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 84
Hepatitis B - Pipeline by GeneCure LLC, H2 2015 85
Hepatitis B - Pipeline by Genexine, Inc., H2 2015 86
Hepatitis B - Pipeline by Gilead Sciences, Inc., H2 2015 87
Hepatitis B - Pipeline by GlaxoSmithKline Plc, H2 2015 88
Hepatitis B - Pipeline by Green Cross Corporation, H2 2015 89
Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H2 2015 90
Hepatitis B - Pipeline by Humabs BioMed SA, H2 2015 91
Hepatitis B - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015 92
Hepatitis B - Pipeline by Immunotope, Inc., H2 2015 93
Hepatitis B - Pipeline by Immunovaccine, Inc., H2 2015 94
Hepatitis B - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 95
Hepatitis B - Pipeline by Indian Immunologicals Limited, H2 2015 96
Hepatitis B - Pipeline by iQur Limited, H2 2015 97
Hepatitis B - Pipeline by ISA Pharmaceuticals B.V., H2 2015 98
Hepatitis B - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 99
Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015 100
Hepatitis B - Pipeline by Johnson & Johnson, H2 2015 101
Hepatitis B - Pipeline by KAEL-GemVax Co., Ltd., H2 2015 102
Hepatitis B - Pipeline by Kineta, Inc., H2 2015 103
Hepatitis B - Pipeline by Leukocare AG, H2 2015 104
Hepatitis B - Pipeline by LG Life Science LTD., H2 2015 105
Hepatitis B - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 106
Hepatitis B - Pipeline by Mologen AG, H2 2015 107
Hepatitis B - Pipeline by Mucosis B.V., H2 2015 108
Hepatitis B - Pipeline by MultiCell Technologies, Inc., H2 2015 109
Hepatitis B - Pipeline by Novira Therapeutics, Inc., H2 2015 110
Hepatitis B - Pipeline by Panacea Biotec Limited, H2 2015 111
Hepatitis B - Pipeline by Pfenex Inc., H2 2015 112
Hepatitis B - Pipeline by PharmaEssentia Corporation, H2 2015 113
Hepatitis B - Pipeline by Profectus BioSciences, Inc., H2 2015 114
Hepatitis B - Pipeline by Redx Pharma Plc, H2 2015 115
Hepatitis B - Pipeline by REPLICor Inc., H2 2015 116
Hepatitis B - Pipeline by Romark Laboratories, L.C., H2 2015 117
Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2015 118
Hepatitis B - Pipeline by SEEK Group, H2 2015 119
Hepatitis B - Pipeline by Sinovac Biotech Ltd., H2 2015 120
Hepatitis B - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2015 121
Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2015 122
Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H2 2015 123
Hepatitis B - Pipeline by TGV-Laboratories, H2 2015 124
Hepatitis B - Pipeline by Theravectys SA, H2 2015 125
Hepatitis B - Pipeline by Transgene SA, H2 2015 126
Hepatitis B - Pipeline by UAB Profarma, H2 2015 127
Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2015 128
Hepatitis B - Pipeline by Viriom Ltd., H2 2015 129
Hepatitis B - Pipeline by VLP Biotech, Inc., H2 2015 130
Hepatitis B - Pipeline by WaterStone Pharmaceuticals, Inc., H2 2015 131
Hepatitis B - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 132
Assessment by Monotherapy Products, H2 2015 133
Assessment by Combination Products, H2 2015 134
Number of Products by Stage and Target, H2 2015 136
Number of Products by Stage and Mechanism of Action, H2 2015 139
Number of Products by Stage and Route of Administration, H2 2015 141
Number of Products by Stage and Molecule Type, H2 2015 143
Hepatitis B Therapeutics - Recent Pipeline Updates, H2 2015 325
Hepatitis B - Dormant Projects, H2 2015 366
Hepatitis B - Dormant Projects (Contd..1), H2 2015 367
Hepatitis B - Dormant Projects (Contd..2), H2 2015 368
Hepatitis B - Dormant Projects (Contd..3), H2 2015 369
Hepatitis B - Dormant Projects (Contd..4), H2 2015 370
Hepatitis B - Dormant Projects (Contd..5), H2 2015 371
Hepatitis B - Dormant Projects (Contd..6), H2 2015 372
Hepatitis B - Dormant Projects (Contd..7), H2 2015 373
Hepatitis B - Dormant Projects (Contd..8), H2 2015 374
Hepatitis B - Discontinued Products, H2 2015 375